CA2498639A1 - Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes - Google Patents

Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes Download PDF

Info

Publication number: CA2498639A1
Authority: CA; Canada
Prior art keywords: niacin; flush; females; sexual dysfunction; blood
Prior art date: 2005-03-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002498639A

Other languages

English (en)

Inventor

J.D. Globus

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-02

Filing date

2005-03-02

Publication date

2006-09-02

2005-03-02 Application filed by Individual filed Critical Individual

2005-03-02 Priority to CA002498639A priority Critical patent/CA2498639A1/fr

2006-09-02 Publication of CA2498639A1 publication Critical patent/CA2498639A1/fr

Status Abandoned legal-status Critical Current

Links

PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 101
235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 89
239000011664 nicotinic acid Substances 0.000 title claims abstract description 89
229960003512 nicotinic acid Drugs 0.000 title claims abstract description 89
201000001880 Sexual dysfunction Diseases 0.000 title claims description 15
231100000872 sexual dysfunction Toxicity 0.000 title claims description 15
238000011282 treatment Methods 0.000 title description 20
230000002265 prevention Effects 0.000 title description 4
230000009469 supplementation Effects 0.000 title description 3
238000000034 method Methods 0.000 claims abstract description 13
210000004392 genitalia Anatomy 0.000 claims abstract description 12
201000001881 impotence Diseases 0.000 claims abstract description 7
230000002093 peripheral effect Effects 0.000 claims abstract description 6
208000004362 Penile Induration Diseases 0.000 claims abstract description 5
208000020758 Peyronie disease Diseases 0.000 claims abstract description 5
208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 4
239000003826 tablet Substances 0.000 claims description 13
208000019901 Anxiety disease Diseases 0.000 claims description 10
230000036506 anxiety Effects 0.000 claims description 9
210000002445 nipple Anatomy 0.000 claims description 6
239000012730 sustained-release form Substances 0.000 claims description 5
230000035945 sensitivity Effects 0.000 claims description 4
238000013268 sustained release Methods 0.000 claims description 4
230000007812 deficiency Effects 0.000 claims description 3
206010047139 Vasoconstriction Diseases 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
230000025033 vasoconstriction Effects 0.000 claims description 2
206010009306 Clitoral engorgement Diseases 0.000 claims 1
239000002775 capsule Substances 0.000 claims 1
210000003756 cervix mucus Anatomy 0.000 claims 1
229940112822 chewing gum Drugs 0.000 claims 1
235000015218 chewing gum Nutrition 0.000 claims 1
230000001010 compromised effect Effects 0.000 claims 1
239000007937 lozenge Substances 0.000 claims 1
239000006187 pill Substances 0.000 claims 1
239000000843 powder Substances 0.000 claims 1
239000000243 solution Substances 0.000 claims 1
230000017531 blood circulation Effects 0.000 abstract description 12
230000002792 vascular Effects 0.000 abstract description 10
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 6
230000009885 systemic effect Effects 0.000 abstract description 5
206010062542 Arterial insufficiency Diseases 0.000 abstract description 4
210000005225 erectile tissue Anatomy 0.000 abstract description 4
229940088594 vitamin Drugs 0.000 abstract description 4
235000013343 vitamin Nutrition 0.000 abstract description 4
239000011782 vitamin Substances 0.000 abstract description 4
229930003231 vitamin Natural products 0.000 abstract description 4
150000003722 vitamin derivatives Chemical class 0.000 abstract description 4
206010054880 Vascular insufficiency Diseases 0.000 abstract description 3
230000001315 anti-hyperlipaemic effect Effects 0.000 abstract description 3
208000023577 vascular insufficiency disease Diseases 0.000 abstract description 3
238000013265 extended release Methods 0.000 abstract description 2
235000019160 vitamin B3 Nutrition 0.000 abstract description 2
239000011708 vitamin B3 Substances 0.000 abstract description 2
238000002560 therapeutic procedure Methods 0.000 description 15
239000008280 blood Substances 0.000 description 14
210000004369 blood Anatomy 0.000 description 14
239000003814 drug Substances 0.000 description 11
210000003899 penis Anatomy 0.000 description 11
150000003180 prostaglandins Chemical class 0.000 description 11
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
229940079593 drug Drugs 0.000 description 10
230000000694 effects Effects 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 9
239000000203 mixture Substances 0.000 description 9
208000031226 Hyperlipidaemia Diseases 0.000 description 8
238000011010 flushing procedure Methods 0.000 description 8
238000009472 formulation Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
230000001568 sexual effect Effects 0.000 description 8
206010020772 Hypertension Diseases 0.000 description 7
230000037007 arousal Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000001856 erectile effect Effects 0.000 description 7
210000005036 nerve Anatomy 0.000 description 7
210000001428 peripheral nervous system Anatomy 0.000 description 7
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
239000006071 cream Substances 0.000 description 5
208000027232 peripheral nervous system disease Diseases 0.000 description 5
208000033808 peripheral neuropathy Diseases 0.000 description 5
230000009467 reduction Effects 0.000 description 5
210000002820 sympathetic nervous system Anatomy 0.000 description 5
MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
235000021323 fish oil Nutrition 0.000 description 4
235000005152 nicotinamide Nutrition 0.000 description 4
239000011570 nicotinamide Substances 0.000 description 4
229960003966 nicotinamide Drugs 0.000 description 4
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
229960004738 nicotinyl alcohol Drugs 0.000 description 4
239000008188 pellet Substances 0.000 description 4
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
230000004044 response Effects 0.000 description 4
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
230000000304 vasodilatating effect Effects 0.000 description 4
230000024883 vasodilation Effects 0.000 description 4
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
229960003692 gamma aminobutyric acid Drugs 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
230000008693 nausea Effects 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
230000035515 penetration Effects 0.000 description 3
210000001215 vagina Anatomy 0.000 description 3
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
208000032544 Cicatrix Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000021663 Female sexual arousal disease Diseases 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101150085511 PEDS1 gene Proteins 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
102100037592 Plasmanylethanolamine desaturase Human genes 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
229960000711 alprostadil Drugs 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000004087 circulation Effects 0.000 description 2
210000003029 clitoris Anatomy 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
230000001113 coital effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
235000020805 dietary restrictions Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000009986 erectile function Effects 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
235000020778 linoleic acid Nutrition 0.000 description 2
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
230000003908 liver function Effects 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229940028444 muse Drugs 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
210000001002 parasympathetic nervous system Anatomy 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
229920003199 poly(diethylsiloxane) Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
201000011264 priapism Diseases 0.000 description 2
230000008569 process Effects 0.000 description 2
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000037387 scars Effects 0.000 description 2
230000036332 sexual response Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229960000835 tadalafil Drugs 0.000 description 2
IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
235000019158 vitamin B6 Nutrition 0.000 description 2
239000011726 vitamin B6 Substances 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
244000202285 Acrocomia mexicana Species 0.000 description 1
235000003625 Acrocomia mexicana Nutrition 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000000412 Avitaminosis Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241001123946 Gaga Species 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
239000009140 Grape Seed Proanthocyanidin Substances 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
241001313288 Labia Species 0.000 description 1
241000489861 Maximus Species 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
108091028051 Numt Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
240000002915 Solanum macrocarpon Species 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010047627 Vitamin deficiencies Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
229960003116 amyl nitrite Drugs 0.000 description 1
230000000049 anti-anxiety effect Effects 0.000 description 1
230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229920002770 condensed tannin Polymers 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000035558 fertility Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229940098326 grape seed proanthocyanidins Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000008949 local secretion Effects 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960001238 methylnicotinate Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229940079463 niacin 100 mg Drugs 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
229940054010 other antipsychotics in atc Drugs 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
210000005164 penile vein Anatomy 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229940068989 potaba Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229960005197 quetiapine fumarate Drugs 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000037390 scarring Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035946 sexual desire Effects 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
229960003310 sildenafil Drugs 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
241000894007 species Species 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
238000012549 training Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960002381 vardenafil Drugs 0.000 description 1
230000006438 vascular health Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
229940094720 viagra Drugs 0.000 description 1
238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002498639A 2005-03-02 2005-03-02 Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes Abandoned CA2498639A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002498639A CA2498639A1 (fr)	2005-03-02	2005-03-02	Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002498639A CA2498639A1 (fr)	2005-03-02	2005-03-02	Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes

Publications (1)

Publication Number	Publication Date
CA2498639A1 true CA2498639A1 (fr)	2006-09-02

Family

ID=36938920

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002498639A Abandoned CA2498639A1 (fr)	2005-03-02	2005-03-02	Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes

Country Status (1)

Country	Link
CA (1)	CA2498639A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1935422A1 (fr) *	2006-12-20	2008-06-25	PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG	Composition pharmaceutique comprenant la nicotinamide ou l'acide nicotinique
EP2057905A1 (fr) *	2007-11-12	2009-05-13	TIMA Foundation	Composition de modération des niveaux de triglycéride et de cholestérol
US8465413B2 (en)	2010-11-25	2013-06-18	Coloplast A/S	Method of treating Peyronie's disease
US9456982B2 (en)	2014-05-18	2016-10-04	Be-Warm Llc	Solid formulations of niacin to counteract cold extremities

2005
- 2005-03-02 CA CA002498639A patent/CA2498639A1/fr not_active Abandoned

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1935422A1 (fr) *	2006-12-20	2008-06-25	PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG	Composition pharmaceutique comprenant la nicotinamide ou l'acide nicotinique
WO2008074860A1 (fr) *	2006-12-20	2008-06-26	Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co. Kg	Composition pharmaceutique comprenant du nicotinamide ou de l'acide nicotinique
EP2057905A1 (fr) *	2007-11-12	2009-05-13	TIMA Foundation	Composition de modération des niveaux de triglycéride et de cholestérol
WO2009062910A1 (fr) *	2007-11-12	2009-05-22	Tima Foundation	Composition pour modérer les taux de triglycérides et de cholestérol
US8465413B2 (en)	2010-11-25	2013-06-18	Coloplast A/S	Method of treating Peyronie's disease
US9456982B2 (en)	2014-05-18	2016-10-04	Be-Warm Llc	Solid formulations of niacin to counteract cold extremities

Publication	Publication Date	Title
Varanese et al.	2010	Treatment of advanced Parkinson′ s disease
TWI583390B (zh)	2017-05-21	富含鞣花單寧之萃取物組成物
Birkmayer et al.	2013	Understanding the Neurotransmitters: Key to the Workings of the Brain
EP4021433A1 (fr)	2022-07-06	Traitement de symptômes induits par le cycle menstruel
JP2008530119A (ja)	2008-08-07	アセチルコリンエステラーゼ阻害剤による微小血管系疾患の治療
Rajput	2021	An overview on dysmenorrhea
CA2498639A1 (fr)	2006-09-02	Utilisation d'acide nicotinique (niacine) comme complement oral pour le traitement et la prevention de dysfonctions sexuelles chez les hommes et les femmes
Houghton et al.	2008	Parkinson's disease: medications
RU2480209C1 (ru)	2013-04-27	Способ лечения нарушений менструального цикла у девушек-подростков с ожирением
Rajiah et al.	2012	Psychological impotence: Psychological erectile dysfunction and erectile dysfunction causes, diagnostic methods and management options
Biziere et al.	1997	Living with Parkinson's disease
RU2445100C2 (ru)	2012-03-20	Консервативный способ комплексного лечения острых и хронических анальных трещин
Bakheit et al.	2011	Successful treatment of severe abulia with co-beneldopa
Schneider	2009	Living with chronic pain: The complete health guide to the causes and treatment of chronic pain
Billot	2019	38 years in the life of a patient with a hepato-digestive disorder. Effects of homeopathic dilutions in space and time
Axe et al.	2020	The Essential Oils Home Remedy Guide
Attanayake et al.	2025	Role of Ayurveda and Sri Lankan traditional medicine in post hemorrhagic stroke rehabilitation-A Case Report
CN109475587B (zh)	2022-04-19	改善睡眠、社会交往、忧虑或担忧的草药方法
Panja et al.	2025	The Holistic Management of Premature Ejaculation Through Ayurveda-A Case Report
Shade	2023	Completing the Sexual Response Cycle Three Times a Week Can Improve Whole Body Health
Bonnard	1999	The Viagra alternative: the complete guide to overcoming erectile dysfunction naturally
CN117398429A (zh)	2024-01-16	一种具有安神作用的中药组合物及其制备方法和用途
CA2942525A1 (fr)	2015-09-17	Composition anti-addictive
Hubble et al.	1996	Medications
Emmanuel	2018	of Neurogenic Bowel

Legal Events

Date	Code	Title	Description
2008-03-03	FZDE	Dead